Day: June 22, 2020

Roflumilast foam potential “Best in Class” topical PDE4 inhibitor in foam formulationSeborrheic dermatitis affects over 6 million U.S. patientsPhase 2 topline data anticipated early in fourth quarter of 2020The Company also announced first patient enrolled in long-term safety studyWESTLAKE VILLAGE, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced it had completed enrollment of its Phase 2 proof of concept clinical trial evaluating roflumilast foam as a potential treatment for seborrheic dermatitis.  Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective...

Inhibigens (inhibitory antigens) are detrimental an otherwise protective immunotherapyInhibigens alter the tumor microenvironment and drive tumor hyperprogressionInhibigens abolish both global and tumor antigen-specific T cell activityCAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today presented preclinical data that offers new and important insights into the biology and behavior of inhibitory neoantigens (Inhibigens™)  at the American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24. The findings build on previous research presented at SITC 2019 which demonstrated that the presence of an Inhibigen in an otherwise protective immunotherapy can completely reverse anti-tumor...

SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today presented preclinical studies highlighting the potential for its lead drug candidate, repotrectinib, to increase the effectiveness of KRAS-G12C and MEK inhibitors in cancer models, and for its next-generation ALK inhibitor candidate, TPX-0131, to overcome ALK-resistant mutations.The studies were included as part of three poster presentations at today’s virtual annual meeting of the American Association for Cancer Research (AACR).“Feedback reactivation and bypass signaling may limit the efficacy of KRAS-G12C and MEK inhibitors against KRAS-driven tumors, and our encouraging preclinical data shows how repotrectinib has the potential...

UNIONDALE, N.Y., June 22, 2020 (GLOBE NEWSWIRE) — Flushing Financial Corporation (the “Company”) (Nasdaq: FFIC), the parent holding company for Flushing Bank (the “Bank”), announced today that the Bank has received funds from the FHLBNY Small Business Recovery Grant Program. These funds are intended to support the financial security and health of workers employed by organizations that have suffered a decrease in revenue as a result of the ongoing COVID-19 crisis. The Bank has begun to disburse the grant money to local small businesses and non-profit organizations in their market area.“Our participation in this grant program allows us to provide much needed support to small businesses and non-profit organizations, both customers and non-customers, in the communities we serve.” stated John R. Buran, President and CEO. “Small businesses...

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today presented preclinical data from the company’s glucocorticoid receptor (GR) antagonist and CD73 inhibitor programs in five poster presentations during the ongoing American Association for Cancer Research (AACR) Virtual Annual Meeting II.“We are pleased to be able to present these compelling preclinical data from our ORIC-101 and CD73 programs, which continue to validate our scientific platform focused on overcoming therapeutic resistance in cancer,” said Lori Friedman, chief scientific officer. “In particular, we are encouraged to see ORIC-101 reversing GR-mediated resistance in a variety of tumor models,...

EMERYVILLE, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, at 10:50 a.m. E.T.The presentation will be webcast and may be accessed through the “Events & Presentations” page on the “investors” section of the Company’s website at http://investors.dynavax.com/events-presentations.About DynavaxDynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following...

The Company reports an annual revenue increase of $1,535,776 year over year!Las Vegas, NV & Hong Kong, June 22, 2020 (GLOBE NEWSWIRE) — 12 ReTech Corporation (OTC: RETC), announced today that it has filed its annual Form 10-K with the United States Securities and Exchange Commission for the year ended December 31, 2019. These financial results represent the combined operations of 12 Hong Kong, Ltd., 12 Japan, Ltd., 12 Europe AG and Emotion Fashion Group, Inc. (“EFG”) during the entire 12 month period ended December 31, 2019 and also include the financial results from the dates of acquisition through December 31, 2019 for Red Wire Group, LLC (“RWG”), Rune NYC, LLC (“Rune”), Bluwire Group, LLC (“Bluwire”) and Social Decay, LLC (“Social Sunday”) which were each acquired on various dates during 2019.For the 12-month period ended...

SAN JOSE, Calif., June 22, 2020 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that  the Company launched a new immunology test product line in China during the week of June 15, 2020.  This immunology test product line consists of multiple government-approved immunology related tests, and relies on AnPac Bio’s novel multi-level, multi-parameter scientific approach and expertise along with our proprietary algorithms.Given the evidence of correlation between degradation in human immune system and cancer occurrence and diseases such as COVID-19, there has been increasing interest in immunology related tests and risk assessments. According...

VANCOUVER, British Columbia, June 22, 2020 (GLOBE NEWSWIRE) — HIRE Technologies Inc. (TSX-V: HIRE) (“HIRE”) and RSI International Systems Inc. (NEX: RSY.H) (“RSI”) have mutually agreed to terminate their agreement to combine or amalgamate, as announced in a press release dated February 21, 2020. Neither party must pay the other a termination fee because of the mutual decision to terminate the agreement.About RSI International SystemsRSI International Systems Inc. sold its only business asset, RoomKeyPMS, in early 2019. The Company is now seeking to use the net sale proceeds to invest in a new business.About HIRE TechnologiesHIRE is focused on the acquisition of information technology, staffing, and HR consulting firms. We provide our partners with meaningful cross-selling opportunities, access to leading technology,...

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that preclinical data from its immuno-oncology microbiome program are currently being featured in an e-poster at the American Association for Cancer Research Virtual Annual Meeting II, June 22-24, 2020. The poster, Discovery and functional validation of a rationally selected, orally administered, live biotherapeutic consortium of commensal bacteria for the treatment of solid tumors, is also available in the Investors section of Assembly’s website: https://investor.assemblybio.com/events-presentations.“There is growing evidence supporting the role of gut commensal...